Effects of weight loss diet therapy on anthropometric measurements and biochemical variables in schizophrenic patients

Nordic Journal of Psychiatry

Volumn 69, Issue 5, 2015, Pages 323-330

  Urhan, Murat ^a   Ergün, Can ^b   Aksoy, Meral ^b   Ayer, Ahmet ^a  

^a Manisa Hospital   (Turkey)

^b BAHCESEHIR UNIVERSITY   (Turkey)

Author keywords

Antipsychotic agents; Ghrelin; Leptin; Obesity; Schizophrenia

Indexed keywords

ALBUMIN; GHRELIN; INSULIN; LEPTIN; LIPID; NEUROLEPTIC AGENT;

ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; DIET THERAPY; DSM-IV; FEMALE; FOOD INTAKE; HUMAN; INSULIN RESISTANCE; NUTRITION EDUCATION; OBESITY; PHYSICAL ACTIVITY; QUESTIONNAIRE; SCHIZOPHRENIA; WEIGHT REDUCTION; BLOOD; COMORBIDITY; MIDDLE AGED; MORPHOMETRICS; OVERWEIGHT; PHYSIOLOGY; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTIPSYCHOTIC AGENTS; BODY WEIGHTS AND MEASURES; COMORBIDITY; FEMALE; HUMANS; MIDDLE AGED; OBESITY; OVERWEIGHT; SCHIZOPHRENIA; TREATMENT OUTCOME; WEIGHT LOSS; YOUNG ADULT;

EID: 84929874052     PISSN: 08039488     EISSN: 15024725     Source Type: Journal    
DOI: 10.3109/08039488.2014.981288     Document Type: Article

References (61)

1. World Health Organization. Obesity: Preventing and managing the global epiDemic report of a WHO consultation on obesity. WHO Technical Report Services 2000 ; 894 : 1-253
2. National Institutes of Health, National Heart, Lung and Blood Institute. Clinical guiDelines on the iDentifi cation, evaluation and treatment of overweight and obesity in adults in eviDence report. Obes Res 1998 ; 6 : 51S-209S
3. Devlin MJ, Yanovski SZ, Wilson GT. Obesity: What mental health professionals need to know. Am J Psychiatry 2000 ; 157 : 854-866
4. Sinha A, Kling S. A review of adolescent obesity, prevalence, etiology and treatment. Obes Surg 2009 ; 19 : 113-120
5. Kaila B, Raman M. Obesity: A review of pathogenesis and management strategies. Can J Gastroenterol 2008 ; 22 : 61-68
6. Pi-Sunyer FX. The obesity epiDemic: Pathophysiology and consequences of obesity. Obes Res 2002 ; 10 : 97S-104S
7. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, et al. Obesity and cardiovascular disease: Pathophysiology, evaluation, and effect of weight loss. Arterioscler Thromb Vasc Biol 2006 ; 26 : 968-976
8. Allison DB, Newcomer JW, Dunn AL, Blumenthal JA, Fabricatore AN, Daumit GL, et al. Obesity among those with mental disorDers: A National Institute of Mental Health meeting report. Am J Prev Med 2009 ; 36 : 341-350
9. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists &North American Association for the Study of Obesity. Consensus Development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004 ; 27 : 596-601
10. Wirshing DA. Schizophrenia and obesity: Impact of antipsychotic medications. J Clin Psychiatry 2004 ; 65 : 13-26
11. Homel P, Casey D, Allison DB. Changes in body mass inDex for individuals with and without schizophrenia, 1987-1996. Schizophr Res 2002 ; 55 : 277-84
12. McCreadie RG. Diet, smoking and cardiovascular risk in people with schizophrenia: Descriptive study. Br J Psychiatr 2003 ; 183 : 534-9
13. Holt RI, Peveler RC. Obesity, serious mental illness and antipsychotic drugs. Diabetes Obes Metab 2009 ; 11 : 665-79
14. Baptista T, Kin NM, Beaulieu S, De Baptista EA. Obesity and related metabolic abnormalities during antipsychotic drug administration: Mechanisms, management and research perspectives. Pharmacopsychiatry 2002 ; 35 : 205-19
15. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al. Antipsychotic-induced weight gain: A comprehensive research synthesis. Am J Psychiatry 1999 ; 156 : 1686-96
16. Kinon BJ, Basson BR, Gilmore JA, Tollefson GD. Long-term olanzapine treatment: Weight change and weight-related health factors in schizophrenia. J Clin Psychiatry 2001 ; 62 : 92-100
17. HenDerson DC, Cagliero E, Gray C, Nasrallah RA, HayDen DL, Schoenfeld DA, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A fi ve-year naturalistic study. Am J Psychiatry 2000 ; 157 : 975-81
18. Horacek J, Bubenikova-Valesova V, Kopecek M, Palenicek T, Dockery C, Mohr P, et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 2006 ; 20 : 389-409
19. Baptista T. Body weight gain induced by antipsychotic drugs: Mechanisms and management. Acta Psychiatr Scand 1999 ; 100 : 3-16
20. Elman I, Borsook D, Lukas SE. Food intake and reward mechanisms in patients with schizophrenia: Implications for metabolic disturbances and treatment with second-generation antipsychotic agents. Neuropsychopharmacology 2006 ; 31 : 2091-120
21. Tardieu S, Micallef J, Gentile S, Blin O. Weight gain profi les of new anti-psychotics: Public health consequences. Obes Rev 2003 ; 4 : 129-38
22. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: A comprehensive literature review. CNS Drugs 2005 ; 19 : 1-93
23. Brar JS, Ganguli R, Pandina G, Turkoz I, Berry S, Mahmoud R. Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorDer. J Clin Psychiatry 2005 ; 66 : 205-12
24. Pendlebury J, Bushe CJ, Wildgust HJ, Holt RI. Long-term maintenance of weight loss in patients with severe mental illness through a behavioural treatment programme in the UK. Acta Psychiatr Scand 2007 ; 115 : 286-94
25. Menza M, Vreeland B, Minsky S, Gara M, Radler DR, Sakowitz M. Managing atypical antipsychotic-Associated weight gain: 12-month data on a multimodal weight control program. J Clin Psychiatry 2004 ; 65 : 471-7
26. Centorrino F, Wurtman JJ, Duca KA, Fellman VH, Fogarty KV, Berry JM, et al. Weight loss in overweight patients maintained on atypical antipsychotic agents. Int J Obes 2006 ; 30 : 1011-16
27. Mauri M, Simoncini M, CastrogioVanni S, Iovieno N, Cecconi D, DellAgnello G et al. A psychoeducational program for weight loss in patients who have experienced weight gain during antipsychotic treatment with olanzapine. Pharmacopsychiatry 2008 ; 41 : 17-23
28. Vreeland B, Minsky S, Menza M, Rigassio Radler D, Roemheld-Hamm B, Stern R. A program for managing weight gain associated with atypical antipsychotics. Psychiatr Serv 2003 ; 54 : 1155-7
29. Wu MK, Wang CK, Bai YM, Huang CY, Lee SD. Outcomes of obese, clozapine-treated inpatients with schizophrenia placed on a six-month diet and physical activity program. Psychiatr Serv 2007 ; 58 : 544-50
30. Skouroliakou M, Giannopoulou I, Kostara C, Hannon JC. Effects of nutritional intervention on body weight and body composition of obese psychiatric patients taking olanzapine. Nutrition 2009 ; 25 : 729-35
31. Janeckova R. The role of leptin in human physiology and pathophysiology. Physiol Res 2001 ; 50 : 443-59
32. Klok MD, Jakobsdottir S, Drent ML. The role of leptin and ghrelin in the regulation of food intake and body weight in humans: A review. Obes Rev 2007 ; 8 : 21-34
33. Frhbeck G, Jebb SA, Prentice AM. Leptin: Physiology and pathophysiology. Clin Physiol 1998 ; 18 : 399-419
34. Blher S, Mantzoros CS. Leptin in humans: Lessons from translational research. Am J Clin Nutr 2009 ; 89 : 991S-7S. 35. BrOmel T, Blum WF, Ziegler A, Schulz E, BenDer M, Fleischhaker C, et al. Serum leptin levels increase rapidly after initiation of clozapine therapy. Mol Psychiatry 1998 ; 3 : 76-80
35. BrOmel T, Blum WF, Ziegler A, Schulz E, BenDer M, Fleischhaker C, et al. Serum leptin levels increase rapidly after initiation of clozapine therapy. Mol Psychiatry 1998 ; 3
36. Schwartz MW, Woods SC, Porte D Jr, Seeley RJ, Baskin DG. Central nervous system control of food intake. Nature 2000 ; 404 : 661-71
37. Kraus T, Haack M, Schuld A, Hinze-Selch D, Khn M, Uhr M, et al. Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am J Psychiatry 1999 ; 156 : 312-14
38. Hgg S, SODerberg S, Ahrn B, Olsson T, MjOrndal T. Leptin concentrations are increased in subjects treated with clozapine or conventional antipsychotics. J Clin Psychiatry 2001 ; 62 : 843-8
39. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptiDe from stomach. Nature 1999 ; 402 : 656-60
40. Roerig JL, Steffen KJ, Mitchell JE, Crosby RD, Gosnell BA. A comparison of the effects of olanzapine and risperidone versus placebo on ghrelin plasma levels. J Clin Psychopharmacol 2008 ; 28 : 21-6
41. TschOp M, Wawarta R, Riepl RL, Friedrich S, Bidlingmaier M, Landgraf R, et al. Post-prandial Decrease of circulating human ghrelin levels. J Endocrinol Invest 2001 ; 24 : RC19-21
42. Aydin S, Ozkan Y, C aylak E, Aydin S. [Ghrelin and its biochemical functions]. Turkiye Klinikleri J Med Sci 2006 ; 26 : 272-83
43. Williams DL, Cummings DE. Regulation of ghrelin in physiologic and pathophysiologic states. J Nutr 2005 ; 135 : 1320-5
44. Weigle DS, Cummings DE, Newby PD, Breen PA, Frayo RS, Matthys CC, et al. Roles of leptin and ghrelin in the loss of body weight caused by a low fat, high carbohydrate diet. J Clin Endocrinol Metab 2003 ; 88 : 1577-86
45. Perez-Iglesias R, Vazquez-Barquero JL, Amado JA, Berja A, Garcia-Unzueta MT, Pelayo-Tern JM, et al. Effect of antipsychotics on peptiDes involved in energy balance in drug-naive psychotic patients after 1 year of treatment. J Clin Psychopharmacol 2008 ; 28 : 289-95
46. Murashita M, Kusumi I, Inoue T, Takahashi Y, Hosoda H, Kangawa K, et al. Olanzapine increases plasma ghrelin level in patients with schizophrenia. Psychoneuroendocrinology 2005 ; 30 : 106-10
47. Hosojima H, Togo T, Odawara T, Hasegawa K, Miura S, Kato Y, et al. Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia. J Psychopharmacol 2006 ; 20 : 75-9
48. Kim BJ, Sohn JW, Park CS, Hahn GH, Koo J, Noh YD, et al. Body weight and plasma levels of ghrelin and leptin during treatment with olanzapine. J Korean Med Sci 2008 ; 23 : 685-90
49. Blouin M, Binet M, Bouchard RH, Roy MA, Desprs JP, Almras N. Improvement of metabolic risk profi le unDer second-generation antipsychotics: A pilot intervention study. Can J Psychiatry 2009 ; 54 : 275-9
50. Ball MP, Coons VB, Buchanan RW. A program for treating olanzapine-related weight gain. Psychiatr Serv 2001; 52: 967-9
51. Daumit GL, Dickerson FB, Wang NY, Dalcin A, Jerome GJ, AnDerson CA, et al. A behavioral weight-loss intervention in persons with serious mental illness. N Engl J Med 2013 ; 368 : 1594-602
52. Koster A, Leitzmann MF, Schatzkin A, Mouw T, Adams KF, Van Eijk JT, et al. Waist circumference and mortality. Am J EpiDemiol 2008 ; 167 : 1465-75
53. Liu Y, Tong G, Tong W, Lu L, Qin X. Can body mass inDex, waist circumference, waist-hip ratio and waist-height ratio predict the presence of multiple metabolic risk factors in chinese subjects? BMC Public Health 2011 ; 11 : 35
54. Zhu S, Wang Z, Heshka S, Heo M, Faith MS, Heymsfi eld SB. Waist circumference and obesity-Associated risk factors among whites in the Third National Health and Nutrition Examination Survey: Clinical action thresholds. Am J Clin Nutr 2002 ; 76 : 743-9
55. Sumner AE, Sen S, Ricks M, Frempong BA, Sebring NG, Kushner H. Determining the waist circumference in African Americans which best predicts insulin resistance. Obesity 2008 ; 16 : 841-6
56. Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am Heart J 2005 ; 150 : 1115-21
57. Mantzoros CS, Magkos F, Brinkoetter M, Sienkiewicz E, DarDeno TA, Kim SY, et al. Leptin in human physiology and pathophysiology. Am J Physiol Endocrinol Metab 2011 ; 301 : E567-84
58. Haupt DW, Luber A, Maeda J, Melson AK, Schweiger JA, Newcomer JW. Plasma leptin and adiposity during antipsychotic treatment of schizophrenia. Neuropsychopharmacology 2005 ; 30 : 184-91
59. Abbenhardt C, McTiernan A, Alfano CM, Wener MH, Campbell KL, Duggan C, et al. Effects of individual and combined dietary weight loss and exercise interventions in postmenopausal women on adiponectin and leptin levels. J Intern Med 2013 ; 274 : 163-75
60. Labayen I, Ortega FB, Ruiz JR, Lasa A, Simn E, Margareto J. Role of baseline leptin and ghrelin levels on body weight and fat mass changes after an energy-restricted diet intervention in obese women: Effects on energy metabolism. J Clin Endocrinol Metab 2011 ; 96 : E996-1000
61. De Luis DA, Sagrado MG, ConDe R, Aller R, Izaola O. Changes of ghrelin and leptin in response to hypocaloric diet in obese patients. Nutrition 2008 ; 24 : 162-6